Cancer chemoprevention: A summary of the current evidence

Anticancer Research

Volumn 28, Issue 3 B, 2008, Pages 1857-1866

  Bonovas, Stefanos ^a,b   Tsantes, Argirios ^b   Drosos, Theofanis ^c   Sitaras, Nikolaos M ^a  

^a Department of Pharmacology ^*  (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

Cancer chemoprevention; Clinical trials; Epidemiological data; Review

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANASTROZOLE; ATORVASTATIN; BETA CAROTENE; CALCIUM; CELECOXIB; EPIGALLOCATECHIN GALLATE; EXEMESTANE; FINASTERIDE; FLAVONOID; IMIQUIMOD; LETROZOLE; LYCOPENE; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; RALOXIFENE; RESVERATROL; ROFECOXIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; SILYMARIN; SOMATOSTATIN DERIVATIVE; STATINE DERIVATIVE; TAMOXIFEN; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D;

BLADDER CANCER; BREAST CANCER; BURNING SENSATION; CANCER INHIBITION; CANCER PREVENTION; CARDIOVASCULAR DISEASE; COLON POLYP; COLORECTAL CANCER; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; GINSENG; HEART FAILURE; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER CANCER; LUNG CANCER; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKIN CANCER; SKIN IRRITATION; STOMACH CANCER; STROKE; TARGET ORGAN; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTICARCINOGENIC AGENTS; HUMANS; NEOPLASMS;

EID: 45949111775     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
3. Lippman SM, Lee JJ and Sabichi AL: Cancer chemoprevention: progress and promise. J Natl Cancer Inst 90: 1514-1528, 1998.
4. Sporn MB: Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36: 2699-2702, 1976.
5. Meyskens FL and Szabo E: How should we move the field of chemopreventive agent development forward in a productive manner? Recent Results Cancer Res 166: 113-124, 2005.
6. Grubbs C, Juliana M, Eto I, Casebolt T, Whitaker L, Canfield G, Manczak M, Steele V and Kelloff G: Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. Anticancer Res 13: 33-36, 1993.
7. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL and Seibert K: Celecoxib inhibits N-butyl-N-(4- hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60: 5599-5602, 2000.
8. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC and Ross RK: Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82: 1364-1369, 2000.
9. Blumentals WA, Foulis PR, Schwartz SW and Mason TJ: Analgesic therapy and the prevention of bladder cancer. Urol Oncol 22: 11-15, 2004.
10. Lotan R: Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst 87: 1655-1657, 1995.
11. Grubbs CJ, Moon RC, Squire RA, Farrow GM, Stinson SF, Goodman DG, Brown CC and Sporn MB: 13-cisVRetinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl) nitrosamine. Science 198: 743-744, 1977.
12. Castelao JE, Yuan JM, Gago-Dominguez M, Skipper PL, Tannenbaum SR, Chan KK, Watson MA, Bell DA, Coetzee GA, Ross RK and Yu MC: Carotenoids/vitamin C and smoking-related bladder cancer. Int J Cancer 110: 417-423, 2004.
13. Zeegers MP, Goldbohm RA and van den Brandt PA: Are retinol, vitamin C, vitamin E, folate and carotenoids intake associated with bladder cancer risk? Results from the Netherlands Cohort Study. Br J Cancer 85: 977-983, 2001.
14. Michaud DS, Pietinen P, Taylor PR, Virtanen M, Virtamo J and Albanes D: Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study. Br J Cancer 87: 960-965, 2002.
15. Decensi A, Torrisi R, Bruno S, Costantini M, Curotto A, Nicolo G, Malcangi B, Baglietto L, Bruttini G, Gatteschi B, Rondanina G, Varaldo M, Perloff M, Malone W and Bruzzi P: Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol Biomarkers Prev 9: 1071-1078, 2000.
16. Byar D and Blackard C: Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 10: 556-561, 1977.
17. Newling DW, Robinson M, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M and Sylvester R: Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 27: 110-116, 1995.
18. Bruemmer B, White E, Vaughan T and Cheney CL: Nutrient intake in relation to bladder cancer among middle-aged men and women. Am J Epidemiol 144: 485-495, 1996.
19. Jacobs E, Henion A, Briggs P, Connell C, McCullough M, Jonas C, Rodriguez C, Calle E and Thun M: Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 156: 1002-1010, 2002.
20. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC and Giovannucci E: Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am J Epidemiol 152: 1145-1153, 2000.
21. Okajima E, Tsutsumi M, Ozono S, Akai H, Denda A, Nishino H, Oshima S, Sakamoto H and Konishi Y: Inhibitory effect of tomato juice on rat urinary bladder carcinogenesis after N-butyl-N-(4-hydroxybutyl)nitrosamine initiation. Jpn J Cancer Res 89: 22-26, 1998.
22. Helzlsouer KJ, Comstock GW and Morris JS: Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. Cancer Res 49: 6144-6148, 1989.
23. Kamat AM and Nelkin GM: Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 66: 1209-1212, 2005.
24. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L and Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998.
25. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC and Wolmark N: Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295: 2727-2741, 2006.
26. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY and Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62, 2005.
27. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E and McTiernan A: Women's Health Initiative. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 63: 6096-6101, 2003.
28. Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro M, Costa A, Marubini E, Sporn MB and De Palo G: Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17: 1065-1071, 2006.
29. Seeger H, Wallwiener D and Mueck AO: Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 111: 47-48, 2003.
30. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J and Soria C: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22: 1139-1148, 2001.
31. Alonso D, Farina H, Skilton G, Gabri M, De Lorenzo M and Gomez D: Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50: 83-93, 1998.
32. Inano H, Suzuki K, Onoda M and Wakabayashi K: Anticarcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats. Carcinogenesis 18: 1723-1727, 1997.
33. Bonovas S, Filioussi K, Tsavaris N and Sitaras NM: Use of Statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23: 8606-8612, 2005.
34. Bonovas S, Filioussi K, Tsavaris N and Sitaras NM: A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes - In reply. J Clin Oncol 24: 2127-2128, 2006.
35. Bonovas S, Filioussi K, Tsavaris N and Sitaras NM: Lipophilic statins merit additional study for breast cancer chemoprevention - In reply. J Clin Oncol 24: 2129-2129, 2006.
36. Bonovas S, Filioussi K, Tsavaris N and Sitaras NM: Statins and breast cancer prevention: time for randomized controlled trials - In reply. J Clin Oncol 24: 2130-2131, 2006.
37. Romney SL, Ho GY, Palan PR, Basu J, Kadish AS, Klein S, Mikhail M, Hagan RJ, Chang CJ and Burk RD: Effects of beta-carotene and other factors on outcome of cervical dysplasia and human papillomavirus infection. Gynecol Oncol 65:483-492, 1997.
38. Keefe KA, Schell MJ, Brewer C, McHale M, Brewster W, Chapman JA, Rose GS, McMeeken DS, Lagerberg W, Peng YM, Wilczynski SP, Anton-Culver H, Meyskens FL and Berman ML: A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 10: 1029-1035, 2001.
39. Mackerras D, Irwig L, Simpson JM, Weisberg E, Cardona M, Webster F, Walton L and Ghersi D: Randomized double-blind trial of beta-carotene and vitamin C in women with minor cervical abnormalities. Br J Cancer 79: 1448-1453, 1999.
40. Butterworth CE Jr, Hatch KD, Soong SJ, Cole P, Tamura T, Sauberlich HE, Borst M, Macaluso M and Baker V: Oral folic acid supplementation for cervical dysplasia: a clinical intervention trial. Am J Obstet Gynecol 166: 803-809, 1992.
41. Butterworth CE Jr, Hatch KD, Macaluso M, Cole P, Sauberlich HE, Soong SJ, Borst M and Baker VV: Folate deficiency and cervical dysplasia. JAMA 267: 528-533, 1992.
42. Childers J, Chu J, Voigt L, Feigl P, Tamimi H, Franklin E, Alberts D and Meyskens F Jr: Chemoprevention of cervical cancer with folic acid: a phase HI Southwest Oncology Group Intergroup study. Cancer Epidemiol Biomarkers Prev 4: 155-159, 1995.
43. Harper D, Franco E, Wheeler C, Ferris D, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho N, Roteli-Martins C, Teixeira J, Blatter M, Korn A, Quint W and Dubin G: Efficacy of a bivalent LI virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757-1765, 2004.
44. Harper D, Franco E, Wheeler C, Moscicki A, Romanowski B, Roteli-Martins C, Jenkins D, Schuind A, Costa Clemens S and Dubin G: Sustained efficacy up to 4.5 years of a bivalent LI virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247-1255, 2006.
45. Sasieni P: Chemoprevention of cervical cancer. Best Pract Res Clin Obstet Gynaecol 20: 295-305, 2006.
46. Longnecker M, Martin-Moreno J, Knekt P, Nomura A, Schober S, Stähelin H, Wald N, Gey K and Willett W: Serum alphatocopherol concentration in relation to subsequent colorectal cancer: pooled data from five cohorts. J Natl Cancer Inst 84: 430-435, 1992.
47. Bostick RM, Potter JD, McKenzie DR, Sellers TA, Kushi LH, Steinmetz KA and Folsom AR: Reduced risk of colon cancer with high intake of vitamin E: the Iowa Women's Health Study. Cancer Res 53: 4230-4237, 1993.
48. Van Poppel G: Carotenoids and cancer: an update with emphasis on human intervention studies. Eur J Cancer 29: 1335-1344, 1993.
49. Hawk ET, Umar A and Viner JL: Colorectal cancer chemoprevention: an overview of the science. Gastroenterology 126: 1423-1447, 2004.
50. Lamprecht SA and Lipkin M: Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 3: 601-614, 2003.
51. Baron J, Beach M, Mandel J, van Stolk R, Haile R, Sandier R, Rothstein R, Summers R, Snover D, Beck G, Bond J and Greenberg E: Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 340: 101-107, 1999.
52. Wallace K, Baron JA, Cole BF, Sandier RS, Karagas MR, Beach MA, Haile RW, Burke CA, Pearson LH, Mandel JS, Rothstein R and Snover DC: Effect of calcium supplementation on the risk of large bowel polyps. J Natl Cancer Inst 96: 921-925, 2004.
53. Grau MV, Baron JA, Sandier RS, Haile RW, Beach ML, Church TR and Heber D: Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 95: 1765-1771, 2003.
54. Grau MV, Rees JR and Baron JA: Chemoprevention in gastrointestinal cancers: current status. Basic Clin Pharmacol Toxicol 98: 281-287, 2006.
55. Bonovas S and Sitaras NM: Anti-inflammatory agents in ageing and age-associated diseases. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 5: 365-373, 2006.
56. Alberts D, Martinez M, Hess L, Einspahr J, Green S, Bhattacharyya A, Guillen J, Krutzsch M, Batta A, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D and Lance P: Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 97: 846-853, 2005.
57. Tung B, Emond M, Haggitt R, Bronner M, Kimmey M, Kowdley K and Brentnall T: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134: 89-95, 2001.
58. Pardi DS, Loftus EV Jr, Kremers WK, Keach J and Lindor KD: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124: 889-893, 2003.
59. Serfaty L, De Leusse A, Rosmorduc O, Desaint B, Flejou J, Chazouilleres O, Poupon R and Poupon R: Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 38: 203-209, 2003.
60. Hebert-Croteau N: A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 7: 653-659, 1998.
61. Grodstein F, Newcomb PA and Stampfer MJ: Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106: 574-582, 1999.
62. Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M, Jackson R, Beresford S, Howard B, Johnson K, Kotchen J and Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333, 2002.
63. Kim KP, Whitehead C, Piazza G and Wargovich MJ: Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci. Anticancer Res 24: 1805-1811, 2004.
64. Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS and Holt PR: Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117: 838-847, 1999.
65. Narisawa T, Morotomi M, Fukaura Y, Hasebe M, Ito M and Aizawa R: Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats. Jpn J Cancer Res 87: 798-804, 1996.
66. Poynter J, Gruber S, Higgins P, Almog R, Bonner J, Rennert H, Low M, Greenson J and Rennert G: Statins and the risk of colorectal cancer. N Engl J Med 352: 2184-2192, 2005.
67. Hawk E and Viner JL: Statins and cancer-beyond the "one drug, one disease" model. N Engl J Med 352: 2238-2239, 2005.
68. Bonovas S, Filioussi K, Flordellis CS and Sitaras NM: Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million subjects. J Clin Oncol 25: 3462-3468, 2007.
69. Corley DA, Kerlikowske K, Verma R and Buffler P: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124: 47-56, 2003.
70. Li JY, Taylor PR, Li B, Dawsey S, Wang GQ, Ershow AG, Guo W, Liu SF, Yang CS and Shen Q: Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 85: 1492-1498, 1993.
71. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M and Li GY: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85: 1483-92, 1993.
72. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J and Wong BC: Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 95: 1784-1791, 2003.
73. Gronich N, Drucker L, Shapiro H, Radnay J, Yarkoni S and Lishner M: Simvastatin induces death of multiple myeloma cell lines. J Investig Med 52: 335-344, 2004.
74. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD and Penn LZ: Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 15: 1398-1407, 2001.
75. Matar P, Rozados VR, Binda MM, Roggero EA, Bonfil RD and Scharovsky OG: Inhibitory effect of lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis 17: 19-25, 1999.
76. Bonovas S, Filioussi K, Tsantes A and Sitaras NM: Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. Br J Clin Pharmacol 64: 255-262, 2007.
77. Chang M, Chen C, Lai M, Hsu H, Wu T, Kong M, Liang D, Shau W and Chen D: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 336: 1855-1859, 1997.
78. Kensler T, Egner P, Wang J, Zhu Y, Zhang B, Lu P, Chen J, Qian G, Kuang S, Jackson P, Gange S, Jacobson L, Munoz A and Groopman J: Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 127: 310-318, 2004.
79. Heathcote EJ: Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 127: 294-302, 2004.
80. Chou R, Clark E and Helfand M: Screening for hepatitis C virus infection: a review of the evidence for the US preventive services task force. Ann Intern Med 140: 465-479, 2004.
81. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029-1035, 1994.
82. Albanes D, Heinonen O, Taylor P, Virtamo J, Edwards B, Rautalahti M, Hartman A, Palmgren J, Freedman L, Haapakoski J, Barrett M, Pietinen P, Malila N, Tala E, Liippo K, Salomaa E, Tangrea J, Teppo L, Askin F, Taskinen E, Erozan Y, Greenwald P and Huttunen J: Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 88: 1560-1570, 1996.
83. Omenn G, Goodman G, Thornquist M, Balmes J, Cullen M, Glass A, Keogh J, Meyskens F, Valanis B, Williams J, Barnhart S and Hammar S: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150-1155, 1996.
84. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH Jr, Barnhart S, Cherniack MG, Brodkin CA and Hammar S: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88: 1550-1559, 1996.
85. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W and Peto R: Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334: 1145-1149, 1996.
86. Van Zandwijk N and Pastorino U: Chemoprevention of lung cancer: soon daily practice? Expert Rev Anticancer Ther 3: 91-98, 2003.
87. Khurana V, Bejjanki H, Caldito G and Owens M: Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 131: 1282-1288, 2007.
88. Bonovas S, Filioussi K, Tsavaris N and Sitaras NM: Statins and cancer risk: a literature-based meta-analysis and metaregression analysis of 35 randomized controlled trials. J Clin Oncol 24: 4808-4817, 2006.
89. Fischer S, Lo H, Gordon G, Seibert K, Kelloff G, Lubet R and Conti C. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25: 231-240, 1999.
90. Pentland A, Schoggins J, Scott G, Khan K and Han R: Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 20: 1939-1944, 1999.
91. Harris R, Beebe-Donk J and Namboodiri K: Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep 8: 655-657, 2001.
92. Ramirez CC, Ma F, Federman DG and Kirsner RS: Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients. Dermatol Surg 31: 748-752, 2005.
93. Guadagni F, Ferroni P, Palmirotta R, Del Monte G, Formica V and Roselli M: Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res 27: 3147-3162, 2007.
94. Collisson EA, Carranza DC, Chen IY and Kolodney MS: Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells. J Invest Dermatol 119: 1172-1176, 2002.
95. Chan K, Oza A and Siu L: The statins as anticancer agents. Clin Cancer Res 9: 10-19, 2003.
96. Demierre MF, Higgins PD, Gruber SB, Hawk E and Lippman SM: Statins and cancer prevention. Nat Rev Cancer 5: 930-942, 2005.
97. Dellavalle R, Drake A, Graber M, Heilig L, Hester E, Johnson K, McNealy K and Schilling L: Statins and flbrates for preventing melanoma. Cochrane Database Syst Rev CD003697, 2005.
98. Nihal M, Ahmad N, Mukhtar H and Wood GS: Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int J Cancer 114: 513-521, 2005.
99. Anstey AV: Systemic photoprotection with alpha-tocopherol (vitamin E) and beta-carotene. Clin Exp Dermatol 27: 170-176, 2002.
100. Fazekas Z, Gao D, Saladi RN, Lu Y, Lebwohl M and Wei H: Protective effects of lycopene against ultraviolet B-induced photodamage. Nutr Cancer 47: 181-187, 2003.
101. Wertz K, Hunziker P, Seifert N, Riss G, Neeb M, Steiner G, Hunziker W and Goralczyk R: beta-Carotene interferes with ultraviolet light A-induced gene expression by multiple pathways. J Invest Dermatol 124: 428-434, 2005.
102. Mochizuki M, Yoo YC, Matsuzawa K, Sato K, Saiki I, Tonooka S, Samukawa K and Azuma I: Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of red ginseng. Biol Pharm Bull 18: 1197-1202, 1995.
103. Niles RM: Vitamin A and cancer. Nutrition 16: 573-576, 2000.
104. Moon TE, Levine N, Cartmel B, Bangert JL, Rodney S, Dong Q, Peng Y and Alberts D: Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 6: 949-956, 1997.
105. Bavinck J, Tieben L, Van der Woude F, Tegzess A, Hermans J, ter Schegget J and Vermeer BJ: Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 13: 1933-1938, 1995.
106. Tangrea J, Edwards B, Taylor P, Hartman A, Peck G, Salasche S, Menon P, Benson P, Mellette J and Guill M: Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. J Natl Cancer Inst 84: 328-332, 1992.
107. McKenna D and Murphy G: Skin cancer chemoprophylaxis in renal transplant recipients: 5 years of experience using low-dose acitretin. Br J Dermatol 140: 656-660, 1999.
108. Levine N, Moon TE, Cartmel B, Bangert JL, Rodney S, Dong Q, Peng Y and Alberts DS: Trial of retinol and isotretinoin in skin cancer prevention: a randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 6: 957-961, 1997.
109. Mittal A, Elmets CA and Katiyar SK: Dietary feeding of proanthocyanidins from grape seeds prevents photocarcinogenesis in SKH-1 hairless mice: relationship to decreased fat and lipid peroxidation. Carcinogenesis 24: 1379-1388, 2003.
110. Barthelman M, Bair WB 3rd, Stickland KK, Chen W, Timmermann BN, Valcic S, Dong Z and Bowden GT: (-)-Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity. Carcinogenesis 19: 2201-2204, 1998.
111. Katiyar S, Agarwal R and Mukhtar H: Inhibition of both stage I and stage II skin tumor promotion in SENCAR mice by a polyphenolic fraction isolated from green tea: inhibition depends on the duration of poly phenol treatment. Carcinogenesis 14: 2641-2643, 1993.
112. Lahiri-Chatterjee M, Katiyar SK, Mohan RR and Agarwal R: A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res 59: 622-632, 1999.
113. Ness R, Grisso J, Vergona R, Klapper J, Morgan M and Wheeler J: Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 12: 307-312, 2001.
114. Siskind V, Green A, Bain C and Purdie D: Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 11: 106-110, 2000.
115. Narod S, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet J and Ponder B: Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339: 424-428, 1998.
116. Rosenberg L, Palmer J, Zauber A, Warshauer M, Lewis J, Strom B, Harlap S and Shapiro S: A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139: 654-661, 1994.
117. Parazzini F, La Vecchia C, Negri E, Bocciolone L, Fedele L and Franceschi S: Oral contraceptive use and the risk of ovarian cancer: an Italian case-control study. Eur J Cancer 27: 594-598, 1991.
118. Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, Tzonou A and Trichopoulos D: Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 49: 61-65, 1991.
119. Gross TP, Schlesselman JJ, Stadel BV, Yu W and Lee NC: The risk of epithelial ovarian cancer in short-term users of oral contraceptives. Am J Epidemiol 136: 46-53, 1992.
120. Rodriguez-Burford C, Barnes M, Oelschlager D, Myers R, Talley L, Partridge E and Grizzle W: Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: preclinical evaluation of NSAIDs as chemopreventive agents. Clin Cancer Res 8: 202-209, 2002.
121. Bonovas S, Filioussi K and Sitaras NM: Do non-steroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol 60: 194-203, 2005.
122. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR and Greenberg ER: Over-the-counter analgesics and risk of ovarian cancer. Lancet 351: 104-107, 1998.
123. Anonymous: NTP Toxicology and Carcinogenesis Studies of Acetaminophen (CAS No. 103-90-2) in F344 Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 394: 1-274, 1993.
124. Bonovas S, Filioussi K and Sitaras NM: Paracetamol use and ovarian cancer risk: a meta-analysis. Br J Clin Pharmacol 62: 113-121, 2006.
125. Wu S, Zhang D, Donigan A, Dawson M, Soprano D and Soprano K: Effects of conformationally restricted synthetic retinoids on ovarian tumor cell growth. J Cell Biochem 68: 378-388, 1998.
126. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro M, Muraca M, Del Vecchio M, Pinto C, D'Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone W and Sporn M: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91: 1847-1856, 1999.
127. De Palo G, Veronesi U, Camerini T, Formelli F, Mascotti G, Boni C, Fosser V, Del Vecchio M, Campa T and Costa A: Can fenretinide protect women against ovarian cancer? J Natl Cancer Inst 87: 146-147, 1995.
128. Wolff R: Chemoprevention for pancreatic cancer. Int J Gastrointest Cancer 33: 27-41, 2003.
129. Thompson I, Goodman P, Tangen C, Lucia M, Miller G, Ford L, Lieber M, Cespedes R, Atkins J, Lippman S, Carlin S, Ryan A, Szczepanek C, Crowley J and Coltman C: The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224, 2003.
130. Tompson TA and Wilding G: Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. Mol Cancer Ther 2:797-803, 2003.
131. Virtamo J, Pietinen P, Huttunen J, Korhonen P, Malila N, Virtanen M, Albanes D, Taylor P and Albert P: Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 290:476-485, 2003.
132. Miller E, Pastor-Barriuso R, Dalai D, Riemersma R, Appel L and Guallar E: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142: 37-46, 2005.
133. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold J, Ross C, Arnold A, Sleight P, Probstfield J and Dagenais G: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293: 1338-1347, 2005.
134. Gupta S, Adhami V, Subbarayan M, MacLennan G, Lewin J, Hafeli U, Fu P and Mukhtar H: Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 64: 3334-3343, 2004.
135. Wechter WJ, Leipold DD, Murray ED Jr, Quiggle D, McCracken JD, Barrios RS and Greenberg NM: E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res 60: 2203-2208, 2000.
136. Mahmud S, Franco E and Aprikian A: Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90: 93-99, 2004.
137. Garcia Rodriguez L and Gonzalez-Perez A: Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 13: 649-653, 2004.
138. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE and Thun MJ: A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 97: 975-980, 2005.
139. Etminan M, Takkouche B and Caamano-Isorna F: The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 13: 340-345, 2004.
140. Ukomadu C and Dutta A: p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of Gl cyclin-dependent kinases. J Biol Chem 278: 43586-43594, 2003.
141. Swinnen J, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W and Verhoeven G: Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 92: 273-279, 2004.
142. Bonovas S, Filioussi K and Sitaras NM: Statin use and the risk of prostate cancer: a meta-analysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer, in press, 2008.